Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T cell exhaustion in reducing T cell responses
View/ Open
Author
Gehad, Ahmed
Jiang, Ying
Calarese, Adam
Teague, Jessica E.
Dorosario, Andrew
Nghiem, Paul
Schanbacher, Carl
Wang, Linda C.
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1038/jid.2013.75Metadata
Show full item recordCitation
Dowlatshahi, M., V. Huang, A. Gehad, Y. Jiang, A. Calarese, J. E. Teague, A. Dorosario, et al. 2013. “Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T cell exhaustion in reducing T cell responses.” The Journal of investigative dermatology 133 (7): 1879-1889. doi:10.1038/jid.2013.75. http://dx.doi.org/10.1038/jid.2013.75.Abstract
Merkel cell carcinomas (MCC) are rare but highly malignant skin cancers associated with a novel polyomavirus. MCC tumors were infiltrated by T cells, including effector, central memory and regulatory T cells. Infiltrating T cells showed markedly reduced activation as evidenced by reduced expression of CD69 and CD25. Treatment of MCC tumors in vitro with IL-2 and IL-15 led to T cell activation, proliferation, enhanced cytokine production and loss of viable tumor cells from cultures. Expanded tumor-infiltrating lymphocytes showed TCR repertoire skewing and upregulation of CD137. MCC tumors implanted into immunodeficient mice failed to grow unless human T cells in the tumor grafts were depleted with denileukin diftitox, suggesting tumor-specific T cells capable of controlling tumor growth were present in MCC. Both CD4+ and CD8+ FOXP3+ regulatory T cells were frequent in MCC. 50% of non-activated T cells in MCC expressed PD-1, a marker of T-cell exhaustion, and PD-L1 and PD-L2 were expressed by a subset of tumor dendritic cells and macrophages. In summary, we observed tumor-specific T cells with suppressed activity in MCC tumors. Agents that stimulate T cell activity, block Treg function or inhibit PD-1 signaling may be effective in the treatment of this highly malignant skin cancer.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691077/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879706
Collections
- HMS Scholarly Articles [17921]
Contact administrator regarding this item (to report mistakes or request changes)